A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)
Phase 1
Recruiting
- Conditions
- Advanced solid tumours
- Registration Number
- 2024-511501-37-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing, recruiting
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie BI 1703880's anti-tumor activity in combination with ezabenlimab for advanced solid tumors?
How does the efficacy of BI 1703880 plus ezabenlimab compare to standard immunotherapy regimens in metastatic cancer patients?
Which biomarkers are being evaluated to identify responders to BI 1703880 and ezabenlimab combination therapy in phase I trials?
What are the most common adverse events associated with BI 1703880 and how are they managed in early-phase cancer trials?
Are there other Boehringer Ingelheim compounds in development for PD-1/L1 checkpoint inhibition in combination with novel small molecule therapies?
Trial Locations
- Locations (4)
Hospital Universitario Hm Sanchinarro
🇪🇸Madrid, Spain
Vall D Hebron Institute Of Oncology
🇪🇸Barcelona, Spain
Hospital Clinico Universitario De Valencia
🇪🇸Valencia, Spain
Fundacion Instituto Valenciano De Oncologia
🇪🇸Valencia, Spain
Hospital Universitario Hm Sanchinarro🇪🇸Madrid, SpainIrene MorenoSite contact0034902107469irene.moreno@startmadrid.com